On April 1, 2026, Cadrenal Therapeutics, Inc. (the "Company") disclosed in its Form 8-K filing that it has entered into a warrant inducement letter agreement with a holder of its existing warrants. This agreement allows the holder to exercise warrants for cash to purchase up to 571,430 shares of the Company's common stock at an adjusted exercise price of $4.50 per share, significantly reduced from the initial price of $16.50. The exercise of these warrants is expected to generate approximately $2.5 million in gross proceeds for the Company, which will be utilized for working capital purposes. The transactions are anticipated to close on April 1, 2026, subject to customary closing conditions. The Company has also agreed to issue new unregistered Series B-1 and Series B-2 common stock purchase warrants to the holder, equal to the number of shares purchased upon the exercise of the existing warrants. These new warrants will be exercisable at the same price of $4.50 per share, with terms of five years and eighteen months, respectively. The Company plans to file a registration statement to register the resale of the new warrant shares within 30 days following the agreement. This strategic move is aimed at enhancing the Company's liquidity position while minimizing dilution for existing shareholders. The agreement reflects the Company's proactive approach to securing necessary funding while maintaining favorable terms for its investors.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.